Lepe José A, Gil-Navarro M Victoria, Santos-Rubio M Dolores, Bautista Javier, Aznar Javier
Servicio de Microbiología, Hospital Universitario Virgen del Rocío, Sevilla, Spain.
Rev Esp Quimioter. 2010 Mar;23(1):43-7.
The objective of the study is to evaluate the ability of standard vancomycin dosing strategies actually recommended to attain the pharmacodynamic target of an area under the curve of vancomycin serum concentration versus time from 0 to 24 hours (AUC(24h)) to minimum inhibitory concentration (MIC) ratio greater than 400:1 for patients with a suspected or documented methicillin-resistant Staphylococcus aureus (MRSA) bacteraemia by individual analysis and Monte Carlo simulation.
The study included all patients admitted with suspected or proven MRSA infection during the years 2007-2008, and who were initially treated with vancomycin at a dose of 30 mg/kg/ day, and underwent pharmacokinetic monitoring. The area under the curve of vancomycin serum concentration versus time from 0 to 24 hours (AUC(24h)) was calculated as daily dose/ clearance total (D(24h)/CL). Additionally, we studied 45 isolates of MRSA obtained from blood cultures in the period 2007-2008. The MIC to vancomycin was determined using Epsilon-test®. The PK-PD parameter calculated was AUC(24h)/MIC. Microsoft Excel was used to perform a 10.000 subject Monte Carlo simulation. An AUC(24h)/MIC > or =400 was assumed as the target attainment.
In the individual study, the percentage of patients with AUC(24h)/ MIC(50/90) > or = 400 was 50%. The probability (%) of attaining AUC(24h)/MIC ratio values > or = 400 by Monte Carlo simulation was of 66%. The vancomycin MIC value from which the scenario would have to wait a suboptimal treatment (target < 90%) was >1 mg/ L.
This study shows that in the population studied to achieve a vancomycin AUC(24h)/MIC > or =400 is not always attained with the standard dose. Therefore, one would expect a high probability of suboptimal vancomycin AUC(24h)/MIC ratios for patients infected with organisms with vancomycin MICs of >1 mg/ L treated with doses of 30 mg/ kg/ day.
本研究的目的是通过个体分析和蒙特卡洛模拟,评估实际推荐的标准万古霉素给药策略对于疑似或确诊耐甲氧西林金黄色葡萄球菌(MRSA)菌血症患者达到万古霉素血清浓度-时间曲线下面积(AUC(24h))与最低抑菌浓度(MIC)之比大于400:1这一药效学目标的能力。
该研究纳入了2007年至2008年期间所有因疑似或确诊MRSA感染入院、初始接受30mg/kg/天剂量万古霉素治疗并接受药代动力学监测的患者。万古霉素血清浓度-时间曲线下面积(AUC(24h))按每日剂量/总清除率(D(24h)/CL)计算。此外,我们研究了2007年至2008年期间从血培养中获得的45株MRSA分离株。使用Epsilon-test®测定万古霉素的MIC。计算的药代动力学-药效学参数为AUC(24h)/MIC。使用Microsoft Excel进行10000例受试者的蒙特卡洛模拟。假定AUC(24h)/MIC>或 =400为目标达成情况。
在个体研究中,AUC(24h)/MIC(50/90)>或 =400的患者百分比为50%。通过蒙特卡洛模拟达到AUC(24h)/MIC比值>或 =400的概率(%)为66%。若要等待次优治疗(目标<90%),万古霉素MIC值需>1mg/L。
本研究表明,在所研究的人群中,使用标准剂量并不总能达到万古霉素AUC(24h)/MIC>或 =400。因此,对于感染万古霉素MIC>1mg/L的微生物且接受30mg/kg/天剂量治疗的患者,预计万古霉素AUC(24h)/MIC比值出现次优情况的概率较高。